Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Prednisolone acetate
Drug ID BADD_D01832
Description Prednisolone acetate is a [prednisolone] molecule bound to an acetate functional group by an ester bond.[L9449] Prednisolone acetate was granted FDA approval in 1955.[L9449]
Indications and Usage For the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.
Marketing Status Prescription; Discontinued
ATC Code A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB15566
KEGG ID D00980
MeSH ID C009935
PubChem ID 5834
TTD Drug ID Not Available
NDC Product Code 62991-1692; 82298-108; 22552-0044; 52128-150; 46439-8761; 11980-180; 11980-174; 50396-7014; 64958-0048; 50090-0561; 38779-0152; 51552-0027; 61314-637; 60722-3006; 60722-2005; 76420-204; 49452-5990; 50090-5275; 72189-055; 68071-2222; 82298-107; 60758-119; 51672-1338; 50090-1912; 50090-0559
Synonyms prednisolone acetate | prednisolone 21-acetate | pred forte | Scherisolone-Kristall suspension
Chemical Information
Molecular Formula C23H30O6
CAS Registry Number 52-21-1
SMILES CC(=O)OCC(=O)C1(CCC2C1(CC(C3C2CCC4=CC(=O)C=CC34C)O)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thrombophlebitis24.01.02.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Uveitis10.02.01.023; 06.04.03.0030.012554%
Vasculitis10.02.02.006; 24.05.02.001--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.0070.069046%
Visual acuity reduced17.17.01.011; 06.02.03.0010.040800%
Visual impairment06.02.06.0080.040800%Not Available
Vitreous floaters06.09.01.0050.006277%
Weight increased13.15.01.006--
Hypoacusis04.02.01.0060.009415%
Oesophagitis ulcerative07.04.05.003--Not Available
Foreign body sensation in eyes06.01.01.0060.021969%Not Available
Acute coronary syndrome02.02.02.015; 24.04.04.011--Not Available
Conjunctival hyperaemia06.04.01.0040.012554%Not Available
Ocular discomfort06.08.03.0080.012554%Not Available
Nerve injury17.02.10.007; 12.01.12.002--Not Available
Growth retardation15.03.01.006--
Anterior chamber cell06.04.10.0010.006277%Not Available
Affect lability19.04.01.001--Not Available
Corneal thinning06.06.03.0090.006277%Not Available
Corneal neovascularisation24.03.07.009; 06.07.01.0030.006277%Not Available
Haemorrhage24.07.01.002--Not Available
Muscle mass15.05.03.018--Not Available
Cystoid macular oedema12.02.02.005; 06.04.06.0100.012554%Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Skin test negative13.06.04.002--Not Available
Embolism24.01.01.009--
Lipid metabolism disorder14.08.04.003--Not Available
Ill-defined disorder08.01.03.049--Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages